- Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX’s Probody ® and Regeneron's Veloci-Bi ® platforms - - CytomX to receive $30 million upfront payment with the potential for up to $2 billion in research, development, regulatory and

- Advancing wholly owned, next-generation conditionally activated therapeutics CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b), with INDs anticipated in 2023 - - CX-904, Company’s first clinical stage Probody T-cell bispecific (EFGRxCD3), continues to advance in Phase 1 dose

- IND filing for CX-801 is anticipated in the second half of 2023 - SOUTH SAN FRANCISCO, Calif. , Nov. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that preclinical data for CX-801, its

SOUTH SAN FRANCISCO, Calif. , Nov. 02, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy , D.Phil ., chief executive officer and chairman, will participate in the following

SOUTH SAN FRANCISCO, Calif. , Nov. 01, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report third quarter 2022 financial results on Tuesday, November 8, 2022, after the close of

- Presentation at ESMO 2022 by Collaborator, Bristol Myers Squibb - - BMS-986249 Phase 2 study ongoing - SOUTH SAN FRANCISCO, Calif. , Sept. 12, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced

- Presentation at World ADC Conference in San Diego - - CX-2051 integrates CytomX core platform expertise to potentially maximize therapeutic window - SOUTH SAN FRANCISCO, Calif. , Sept. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally

- Recently-announced company restructuring focuses internal efforts on wholly-owned next-generation conditionally activated therapeutics, extending cash runway to 2025 - - New INDs for two next-generation product candidates anticipated in 2023 - - Continued progress with partnered clinical

SOUTH SAN FRANCISCO, Calif. , Aug. 03, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will virtually participate in the

SOUTH SAN FRANCISCO, Calif. , July 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report second quarter 2022 financial results on Thursday, August 4, 2022, after the close of